ArticleJournal of clinical medicine2019
Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton's Jelly, an Extraembryonic Source.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- In vitro assays for investigating the immunomodulatory properties of human mesenchymal stromal cells.Stem cell research & therapy · 2026Review
- Combined effects of mesenchymal stromal cells and antibiotic therapy on Enterobacter ventilator-associated pneumonia in rabbits.Respiratory research · 2026Article
- Manufacturing mesenchymal stromal cells in a microcarrier-microbioreactor platform can enhance cell yield and quality attributes: case study for acute respiratory distress syndrome.Journal of translational medicine · 2024Article
- A GMP-compliant manufacturing method for Wharton's jelly-derived mesenchymal stromal cells.Stem cell research & therapy · 2024Article
- Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources.Heliyon · 2024Article
- Scale-Up of Academic Mesenchymal Stromal Cell Production.Journal of clinical medicine · 2023Article
- IL-6 and TGF-β-Secreting Adoptively-Transferred Murine Mesenchymal Stromal Cells Accelerate Healing of Psoriasis-like Skin Inflammation and Upregulate IL-17A and TGF-β.International journal of molecular sciences · 2023Article
- Human Mesenchymal Stromal Cells Derived from Perinatal Tissues: Sources, Characteristics and Isolation Methods.The Malaysian journal of medical sciences : MJMS · 2023Review
- Potential mechanisms and therapeutic targets of mesenchymal stem cell transplantation for ischemic stroke.Stem cell research & therapy · 2022Review
- Article
- Mesenchymal stem cell-mediated transfer of mitochondria: mechanisms and functional impact.Cellular and molecular life sciences : CMLS · 2022Review
- Role of extracellular vesicles from adipose tissue- and bone marrow-mesenchymal stromal cells in endothelial proliferation and chondrogenesis.Stem cells translational medicine · 2021Article
- Extracellular vesicles derived from CD73 modified human umbilical cord mesenchymal stem cells ameliorate inflammation after spinal cord injury.Journal of nanobiotechnology · 2021Article
- Insight into Hypoxia Stemness Control.Cells · 2021Review
- Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome.Antibiotics (Basel, Switzerland) · 2021Article
- Regenerative Approaches and Future Trends for the Treatment of Corneal Burn Injuries.Journal of clinical medicine · 2021Review
- Cross-Talk Between Mesenchymal Stromal Cells (MSCs) and Endothelial Progenitor Cells (EPCs) in Bone Regeneration.Frontiers in cell and developmental biology · 2021Review
- Comparison of similar cells: Mesenchymal stromal cells and fibroblasts.Acta histochemica · 2020Review
- Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.Stem cells translational medicine · 2020Article
- Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many clinical trials report mesenchymal stem/stromal cells (MSCs) efficacy in various indications. Therefore, standardization of MSC production becomes necessary. MSC properties are impacted by tissue origin, especially if they are from extraembryonic tissue or adult sources. For this reason, we evaluated the impact of MSC tissue origin on production.
methodsThree productions of MSC from Wharton's Jelly (WJ) or from bone marrow (BM) were performed according to good manufacturing practice. The identity (phenotype, differentiation, and clonogenic capacities), safety (karyotype, telomerase activity, sterility, and donor qualification), and functionality (viability, mixed lymphocyte reaction) of each cell batch were analyzed.
resultsSlight differences between MSC sources were observed for phenotype, telomerase activity, and clonogenic capacities.
conclusionBoth sources have made it possible to quickly and easily obtain clinical grade MSC. However, as availability of the source is thought to be essential, WJ seems more advantageous than BM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.